A post hoc analysis of the SLIM LIVER study provides preliminary evidence that the GLP-1 receptor agonist (GLP-1 RA) semaglutide may influence biological aging trajectories in people living with HIV (PWH). PWH often exhibit an accelerated aging phenotype—averaging 3 to 7 years beyond their chronological age—driven by chronic immune activation and metabolic dysregulation. This study investigated whether 24 weeks of low-dose semaglutide (1.0 mg weekly) could modify this trajectory by tracking three “epigenetic clocks”: DunedinPACE, PCGrimAge, and PCDNAmTL.
While the overall group showed minimal median changes in biological age, individual responses varied significantly. Specifically, 41.5% of participants experienced a decrease in DunedinPACE, a third-generation biomarker that measures the current “pace of aging”. Crucially, those who slowed their pace of aging also achieved significantly greater reductions in intrahepatic triglyceride (IHTG) content. This suggests that the metabolic benefits of GLP-1 RAs are not just systemic but may be reflected in the very rate at which cellular damage accumulates.
Furthermore, nearly half of the participants showed an increase in PCDNAmTL, a methylation-derived estimate of telomere length. Increased telomere length correlated with improved gait speed, a robust clinical predictor of longevity and physical resilience. These findings indicate that the “gerotherapeutic” potential of semaglutide extends beyond weight loss, potentially offering organ-specific protection for the liver and musculoskeletal system. However, because the study lacked a control arm and utilized a modest sample size, these signals remain exploratory rather than definitive.
Actionable Insights
-
Liver Fat as an Aging Driver: Reducing liver fat (IHTG) through GLP-1 RA therapy may directly correlate with a slower pace of biological aging (DunedinPACE), suggesting MASLD management is a priority for longevity.
-
Gait Speed as a Tracking Metric: Physical function, specifically gait speed, appears linked to telomere maintenance (PCDNAmTL) during semaglutide treatment; practitioners should monitor mobility as a proxy for biological age responsiveness.
-
Precision Geroscience: Epigenetic biomarkers like DunedinPACE may eventually help clinicians identify “responders” who gain the most biological protection from GLP-1 RAs beyond mere glucose control.
-
Dose Considerations: Even a relatively low dose of semaglutide (1.0 mg) can trigger beneficial epigenetic shifts, though higher doses (2.4 mg) typically used for obesity might produce more robust signals.
-
HIV-Specific Aging: For PWH, semaglutide offers a potential tool to mitigate the 7.5-year average epigenetic age acceleration observed in this cohort.
Source:
- Open Access Paper: Pilot study of epigenetic aging and treatment response to semaglutide in the SLIM LIVER study
- Institutions: Led by University of California San Diego and University of Colorado Anschutz Medical Campus, in collaboration with several US-based medical schools.
- Country: United States.
- Journal Name: npj Aging.
- Impact Evaluation: The impact score (CiteScore/JIF) of this journal is approximately 5.8–9.2, evaluated against a typical high-end range of 0–60+ for top general science, therefore this is a High impact journal within the specialty field of gerontology and aging biology.